WASHINGTON (AP) — President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for the popular obesity treatments Zepbound and Wegovy. Known as GLP-1 receptor agonists, the drugs have soared in popularity in recent years, but patient access has been a consistent problem because of [...]

See Full Page